Physician profile
Vikas Gupta
NPI 1255613527
$2,356.84
in general payments reported to CMS, 2019-2025
29 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $70.64 · 2021: $436 · 2022: $557 · 2023: $532 · 2024: $320 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.17 |
| Education | $160.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $356.03 | 2019-2024 | Xarelto |
| Neurocrine Biosciences, INC. | $326.78 | 2023-2025 | Ingrezza |
| Pfizer INC. | $255.09 | 2019-2022 | |
| Novo Nordisk INC | $182.74 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $177.80 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $136.65 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Janssen Biotech, INC. | $125.86 | 2023 | Tecvayli, Darzalex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.81 | 2019-2025 | Jardiance |
| Intuitive Surgical, INC. | $77.29 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $71.97 | 2020-2022 | |
| Dexcom, INC. | $69.35 | 2021-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $45.44 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.40 | 2022 | |
| Inogen, INC. | $39.44 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Mylan Specialty L.P. | $38.64 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $38.57 | 2021 | |
| Lilly USA, LLC | $30.25 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $28.61 | 2021-2023 | Otezla, Repatha |
| Philips North America LLC | $27.85 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.48 | 2024-2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $18.89 | 2022 | |
| Ossur Americas, INC. | $17.45 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.40 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $17.31 | 2019 | |
| Corcept Therapeutics | $16.36 | 2025 | Korlym |
| Boston Scientific Corporation | $16.20 | 2022 | |
| Allergan, INC. | $13.93 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $11.49 | 2021 | |
| Intra-Sana Laboratories | $10.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.